EOS Clinical Trials

204 recruitingLast updated: May 11, 2026

There are 204 actively recruiting eos clinical trials across 43 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, Philadelphia, Pennsylvania, United States, Atlanta, Georgia, United States. Updated daily from ClinicalTrials.gov.


EOS Trials at a Glance

204 actively recruiting trials for eos are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Phase 2 with 45 trials, with the heaviest enrollment activity in Boston, Philadelphia, and Atlanta. Lead sponsors running eos studies include National Institute of Allergy and Infectious Diseases (NIAID), Children's Hospital Medical Center, Cincinnati, and Karolinska Institutet.

Treatments under study

About EOS Clinical Trials

Looking for clinical trials for EOS? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new EOS trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about EOS clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 204 trials

Recruiting
Phase 1Phase 2

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Not Applicable

The Esophageal String Test as a Diagnostic Screening Tool for Eosinophilic Esophagitis Among Africans With Dysphagia in Mali and the United States

eosinophilic esophagitisDysphagia
National Institute of Allergy and Infectious Diseases (NIAID)70 enrolled3 locationsNCT07027826
Recruiting

A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression

EosinophiliaHypereosinophilic Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)50 enrolled1 locationNCT00091871
Recruiting
Phase 1

Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection

EBVEpstein-Barr Virus InfectionInfectious Mononucleosis+1 more
National Institute of Allergy and Infectious Diseases (NIAID)750 enrolled1 locationNCT06908096
Recruiting
Phase 2Phase 3

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

Metastatic OsteosarcomaHigh Grade OsteosarcomaLocalized Osteosarcoma+1 more
National Cancer Institute (NCI)1,122 enrolled194 locationsNCT05691478
Recruiting
Not Applicable

Pediatric Eosinophilic Esophagitis (pedEoE): Effect of Allergen Heat Denaturation on EoE Remission: a Pilot Trial

eosinophilic esophagitis
Universitaire Ziekenhuizen KU Leuven36 enrolled1 locationNCT06381219
Recruiting
Phase 3

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

OsteosarcomaMetastatic Malignant Neoplasm in the LungMetastatic Osteosarcoma
Children's Oncology Group62 enrolled232 locationsNCT05235165
Recruiting
Phase 2

Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents

Hypereosinophilic Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)30 enrolled1 locationNCT06477653
Recruiting
Phase 1Phase 2

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 1

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

SarcomaOsteosarcomaNeuroblastoma
Stanford University41 enrolled1 locationNCT06500819
Recruiting
Phase 1

Safety and Efficacy of DIT309 in Advanced Bone and Soft Tissue Sarcomas

Soft Tissue SarcomaOsteosarcoma
Tcelltech Inc.15 enrolled1 locationNCT07052383
Recruiting
Phase 2

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

eosinophilic esophagitis
Phathom Pharmaceuticals, Inc.80 enrolled41 locationsNCT06851559
Recruiting
Phase 1Phase 2

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

Relapsed / Refractory Osteosarcoma
Lantheus Medical Imaging55 enrolled2 locationsNCT07357519
Recruiting

Outcomes After Tracheal Cannula Removal

Tracheostomy
Katharina Winiker150 enrolled1 locationNCT06047665
Recruiting

Activation and Function of Eosinophils in Conditions With Blood or Tissue Eosinophilia

Immune System DiseasesEosinophiliaHelminthiasis+2 more
National Institute of Allergy and Infectious Diseases (NIAID)800 enrolled1 locationNCT00001406
Recruiting
Phase 3

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

eosinophilic esophagitis
Dr. Falk Pharma GmbH308 enrolled26 locationsNCT06596252
Recruiting
Phase 2

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Eosinophilic Asthma
Kymera Therapeutics, Inc.264 enrolled17 locationsNCT07323654
Recruiting

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

Eosinophilic Esophagitis (EoE)
Regeneron Pharmaceuticals350 enrolled54 locationsNCT06693531
Recruiting
Phase 1Phase 2

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

AngiosarcomaLiposarcomaAdipocytic Neoplasm+6 more
St. Jude Children's Research Hospital139 enrolled6 locationsNCT06239272
Recruiting

Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas

OsteosarcomaChondrosarcomaBone Sarcoma+3 more
Memorial Sloan Kettering Cancer Center300 enrolled5 locationsNCT03442465